Eliem Therapeutics, Inc. (NASDAQ:ELYM) EVP Sells $39,500.46 in Stock

Eliem Therapeutics, Inc. (NASDAQ:ELYM) EVP Valerie Morisset sold 5,931 shares of the firm’s stock in a transaction that occurred on Tuesday, July 9th. The shares were sold at an average price of $6.66, for a total transaction of $39,500.46. Following the completion of the sale, the executive vice president now directly owns 444,683 shares in the company, valued at $2,961,588.78. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Valerie Morisset also recently made the following trade(s):

• On Thursday, July 11th, Valerie Morisset sold 50,000 shares of Eliem Therapeutics stock. The shares were sold at an average price of $7.11, for a total transaction of $355,500.00.
• On Friday, July 5th, Valerie Morisset sold 12,342 shares of Eliem Therapeutics stock. The shares were sold at an average price of $7.06, for a total transaction of $87,134.52.
• On Wednesday, July 3rd, Valerie Morisset sold 50,000 shares of Eliem Therapeutics stock. The shares were sold at an average price of $6.76, for a total transaction of $338,000.00.

Eliem Therapeutics Price Performance

Shares of NASDAQ ELYM opened at $7.22 on Friday. Eliem Therapeutics, Inc. has a one year low of $2.35 and a one year high of $11.55. The firm’s 50 day simple moving average is $7.87 and its two-hundred day simple moving average is $4.83. The stock has a market capitalization of $214.80 million, a P/E ratio of -13.62 and a beta of -0.33.

Eliem Therapeutics (NASDAQ:ELYM) last issued its earnings results on Wednesday, May 15th. The company reported ($0.06) earnings per share (EPS) for the quarter.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Eliem Therapeutics stock. Cerity Partners LLC purchased a new position in Eliem Therapeutics, Inc. (NASDAQ:ELYM) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 13,821 shares of the company’s stock, valued at approximately $37,000. Cerity Partners LLC owned 0.05% of Eliem Therapeutics as of its most recent SEC filing. Institutional investors and hedge funds own 69.76% of the company’s stock.

Eliem Therapeutics Company Profile

Eliem Therapeutics, Inc, a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.